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ABSTRACT 
 
 
  
 The purpose of this project was to investigate the topic of stem cells and to determine the 
impact of this controversial technology on society.  The technology itself was investigated by 
documenting the various types of stem cells, describing their various medical potencies and 
listing which diseases have already been treated by stem cells.  The effect on society was 
investigated through a discussion of their complex ethical and legal issues. 
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PROJECT OBJECTIVES 
 
 
 The objective of this IQP project was to examine the topic of stem cells, and to discuss 
the effect of this controversial new technology on society.  The purpose of chapter-1 was to 
describe how stem cells are classified and their sources and potencies.  Chapter-2‟s purpose was 
to document the types of experiments that stem cells have successfully been used for.  Chapter-
3‟s purpose was to examine stem cell ethics, and chapter-4 examined the legal issues of stem 
cells. 
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CHAPTER-1:  STEM CELL TYPES 
Kathleen Foust 
 
Stem Cell Introduction 
Originating around the late 1800s, the topic of Stem Cells is a rapidly growing area in 
science.  Stem cells have the extraordinary capability to change or differentiate into different cell 
types in the body.  Since they have the ability to replace dead cells, in adult tissues they serve as 
an internal repair system, and this repair function is the basis of the new field of regenerative 
medicine.  When a stem cell divides, it can create another stem cell, or it can create a more 
specialized cell for the body, such as a blood or skin cell. This asymmetric cell division 
(producing two cell types) is an important characteristic of stem cells since they are able to 
divide and repair indefinitely.  The challenges of research labs are to learn to isolate them, and 
once isolated learn to grow and differentiate them.  The purpose of this chapter is to describe the 
various types of stem cells as an introduction to later chapters on their applications, ethics, and 
legalities.  Special attention will be paid to describing their various potencies, as this topic 
directly relates to their ability to cure specific types of diseases. 
Contrary to popular belief there are numerous types of stem cells. This fact strongly 
affects the stem cell debate, as only one type of stem cell destroys an embryo to obtain them. 
Additionally as you will see in a later chapter, even some religions allow for the use of embryo-
destroyed stem cells. The four main types of stem cells are:  embryonic stem cells (ESCs), adult 
stem cells (ASCs), induced pluripotent stem (iPS) cells, and parthenogenetic ES cells. 
Embryonic stem cells come from the early stages of development, and an embryo is usually 
destroyed to obtain them, so these cells are the most controversial. Adult stem cells are derived 
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from an adult organism, and they serve as the tissues repair and replacement cells. Induced 
pluripotent stem cells, are created from typically adult skin cells that are de-differentiated by 
transfection with genes.  Parthenogenetic ES cells are derived from parthenotes, chemically-
treated eggs that divide without fertilization to make a blastocyst from which ES cells are 
obtained.  Stem cell research in the past decade has grown rapidly into one of the most 
interesting and researched topics in all of science.  Stem cell research holds promise for many 
cures, treatments, and solutions to modern health problems. 
 
Stem Cell Potencies 
Different stem cell types have different potencies.  Totipotent stem cells have the ability 
to make the entire embryo and extra-embryonic tissue.  The only truly totipotent cells are newly 
fertilized cells though the 8-cell stage.  Pluripotent stem cells have the capability to transform 
into any tissue in the body except the placenta.  ES cells are of this type. Because ES cells have 
the ability to repair any tissue in the body, these cells are also the most medically useful.  
Multipotent stem cells have the capacity to make several types of related cells.  For example, 
hematopoietic stem cells (HSCs) can form all of the cellular components of blood, including red 
blood cells, numerous types of white blood cells, and platelets.  Mesenchymal stem cells (MSCs) 
can form several types of mesodermal derived tissues. Also neural stem cells (NSCs) can form 
and repair several parts of the nervous system. Unipotent stem cells only have the ability to make 
one type of cell, usually the same tissue the cell is isolated from, and so these cells are the least 
useful medically. It is important for scientists to understand which stem cells have specific 
potencies to know which diseases they might treat.  Scientists are also working to develop 
protocols to induce stem cells into more than one potency. 
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Embryonic Stem Cells 
 Embryonic Stem Cells (ESCs) are derived from in vitro fertilized (IVF) embryos.  Mouse 
ESCs were first isolated independently by two labs (Martin, 1981; Evans and Kaufman, 1981), 
but human ESCs were not isolated and grown until seventeen years later (Thomson et al., 1998).  
Egg and sperm from donors are united in vitro to make a zygote (Figure-1, diagram upper left).  
The zygote is grown about 3-5 days to make a hollow ball of cells termed a blastocyst (diagram 
center).  The blastocyst contains the inner cell mass, the blastocoel (cavity), and the trophoblast 
(cells lining the cavity).  The inner cell mass (blue in the diagram) is the cluster of cells that 
gives rise to the embryo and then the fetus, the blastocoel is the fluid filled cavity for an early 
preimplantation stage, and the trophoblast is the outer cell layer of the blastocyst that is 
responsible for implantation and which develops into the extraembryonic tissues (NIH, 2010). 
The inner cell mass contains the ESCs.  Once the blastocyst is 3 to 5 days old, the inner cell mass 
is transferred into a laboratory culture dish (lower diagram) that contains a culture medium, 
nutrients, and a feeder layer.  The feeder layer provides a surface to which the ES cells attach, 
and also provides growth factors.  
 
 
 
Figure-1:  Derivation of Embryonic Stem Cells.  A newly fertilized 
egg (upper left) is grown about 3-5 days to make the blastocyst 
(diagram center) from which ES cells are derived from the inner cell 
mass (blue).  The ES cells are grown in a co-culture with mouse 
fibroblasts or other human cells to provide an attachment surface and 
growth factors.  (Yu and Thomson, 2006) 
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 Once many cell culture dishes are grown, this establishes an embryonic stem cell line. 
Establishing cell lines is important, because these lines can be shipped to other labs or hospitals 
where they can expand them further for experiments.  The best ES cell lines are immortal and 
can provide the large numbers of cells needed for therapy implantation. 
 As mentioned previously, ES cells are pluripotent, and can generate any cell in the body 
except for the placenta.  These cells can give rise to all three embryoninc germ layers, the 
ectoderm, mesoderm and endoderm (Yu and Thomson, 2006).  Establishing procedures for 
getting ES cells to differentiate into specific cell types is the subject of current research, and will 
be discussed in detail in Chapter-2 Stem Cell Applications for specific diseases.  But in general, 
the ES cells are treated in the culture dishes with different growth factors or specific genes are 
inserted to produce proteins that change the undifferentiated cells into the specific cells that are 
needed (NIH, 2010).   It is imperative that researchers find the specific laboratory protocols for 
turning ES cells into the differentiated ones so they can be used in therapy.   
 Although ES cells are the most medically potent because they destroy an embryo to 
obtain them, they come with ethical concerns.  This topic will be discussed in detail in Chapter-3 
Stem Cell Ethics, but briefly individuals that argue an IVF embryo has the same rights as a living 
human are against working with ES cells.  The main controversy focuses on when life begins, 
and should an embryo be used to save other lives.   
 
iPS Cells   
 Induced pluripotent stem (iPS) cells are one of the hottest topics in all of stem cell 
research today.  Human iPS cells were first derived in 2007 from the facial skin cells of a 36 year 
old woman and a 69 year old man (Takahashi et al., 2007).  In this process, skin fibroblast cells 
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are transfected with genes encoding transcription factor proteins that help induce a de-
differentiation of the skin cells to make ES-like pluripotent cells.  In some respects, the scientists 
created these iPS cells by erasing the cells‟ “memory”, causing them to go back to their 
embryonic state where they could be reprogrammed into the type of cell needed for therapy 
(Vogel, 2008).  The initial procedure used four transcription factor genes for Oct3/4, Sox2, Klf4, 
and c-Myc.  However, these iPS cells when implanted in mice caused tumors, so subsequent 
protocols omited the c-Myc component to prevent tumor formation (Nakagawa et al., 2008).   
 The excitement for these cells is if they are truly pluripotent, they can be used for 
therapies as a replacement for the more ethically problematic embryo-derived ES cells.  No 
embryo is destroyed to obtain iPS cells; iPS cells are created from adult cells. Moreover, the 
genotype of the iPS cell line matches that of the donor skin cell, so a specific patient‟s own skin 
cells could be used to derive an iPS line for treating that person‟s disease, without having the iPS 
cells rejected from the body.  So much current research is focused on the exact potency of iPS 
cells.   One key finding is that mouse iPS cells have the ability to make an new entire new 
mouse, so this demonstrates a very high level of potency of the mouse iPS cells (Boland et al., 
2009).  But some labs find that human iPS cells divide slower and are less robust than embryo-
derived ES cells (Dolgin, 2010). Researchers are continuing to try to create rapidly dividing 
human iPS cells for human treatments.  
 
Adult Stem Cells 
Adult stem cells (ASCs), also called somatic stem cells, maintain homeostasis in the body 
by replacing damaged or dead cells.  Somatic cells are any type of cell in the body other than the 
gametes.  Compared to ES cells, ASCs are less potent, harder to isolate, and harder to grow.  In 
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fact, scientists are still trying to determine exactly which adult tissues contain ASCs.  The origin 
of adult stem cells in some mature tissues is still under investigation (NIH, 2010).  Well proven 
types of ASCs include hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), 
neuronal stem cells, and epithelial stem cells (NIH, 2010).  But no embryo is destroyed to obtain 
ASCs, so scientists would like to work with these cells so long as they are potent enough to treat 
a specific disease. The fact that they do not destroy embryos makes ASCs more marketable since 
they don‟t have an ethical conflict. Adult stem cells are also important because they limit the risk 
for rejection from the body.  Graft-versus-host disease (GVHD) is a potential risk with all stem 
cell implants, but if taken from a patient‟s own body and expanded the incidence of GVHD is 
minimal (Mayo, 2010). 
ASCs are difficult to isolate because they are so rare in the body.  For example, neuronal 
stem cells have been estimated to represent about 0.001% of all adult brain cells.  The ASCs are 
surrounded by large numbers of differentiated cells, and they become differentiated only when 
the surrounding tissue and cells need them.  These surrounding cells and the low abundance of 
ACSs make it more difficult to harvest ASCs than ES cells. 
 
Hematopoietic Stem Cells 
The world‟s most characterized type stem cells are hematopoietic stem cells (HSCs).  
These cells have been used for over 50 years now in bone marrow transplants to treat specific 
types of blood disorders (Abbott, 2003; Medscape, 2005).  Figure-2 shows how multipotent 
HSCs differentiate into different types of blood cells, and how stromal stem cells differentiate 
into cartilage (NIH, 2010).  HSCs are traditionally obtained from bone marrow (as shown in the 
diagram), but more recently they are also obtained from umbilical cord blood, or from peripheral 
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blood in people treated with hormones to release HSCs into the periphery from marrow.  HSC 
transplants are routinely used to treat specific types of blood cancers, especially leukemia, and 
other blood disorders (HSCs, 2005).  Thus, HSCs are a very clear example of how stem cells are 
already being used to treat some diseases.  With respect to current HSC research, some scientists 
have been looking into turning HSCs into other types of stem cells to be used in treatments 
(HSCs, 2005).  
 
 
 
Figure-2:  Differentiation of Hematopoietic Stem 
Cells.  HSCs are typically  present in bone marrow 
(diagram left).  The HSCs for myeloid and lymphoid 
precursor cells (diagram center) that differentiate 
into all the cellular components of blood.   (NIH, 
2010) 
 
 
 
 
 
Mesenchymal Stem Cells 
 Mesenchymal Stem Cells (MSCs) are adult stem cells with the ability to form many 
different types of tissue including osteocytes, chrondrocytes, adipocytes, astrocytes, 
oligodendrocytes, and skeletal, smooth, and cardiac muscle (MSCs, 2009).  Because MSCs can 
form so many different types of tissues yet are adult stem cells, these cells have recently been the 
subject of much research as possible replacements for ES cells, especially for bones and the 
skeletal system.  
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Neuronal Stem Cells 
 The nervous system has its own type of stem cells called neuronal stem cells (NSCs). 
Before the discovery of NSCs, scientists held the belief that the human brain and spinal cord 
could not regenerate (Rebuilding, 2005).  Adult NSCs are already being used to treat animal 
models for Parkinson‟s disease, as we discussed in Chapter-2, but have not yet been tested on 
humans.  But NSCs are very difficult to isolate, so much research focuses on this topic.   
 
Epithelial Stem Cells 
 Epithelial Stem Cells form 60% of the differentiated cells in the body; they form cells  
covering the internal and external surfaces of the body (The Adult, 2005).   Covering surfaces are 
constantly being replaced in adult tissue from the action of epithelial stem cells, so the hope is to 
isolate them to treat skin disorders or burn patients (The Adult, 2005).  
 
Chapter-1 Conclusion 
 As documented in this chapter, a variety of stem cell types exist, each with different 
potencies and ethics.  ES cells have the best medical potency as they can form any tissue in the 
body, but they come with strong ethical concerns since embryos are destroyed to isolate ES cells.  
iPS cells are induced from skin fibroblast cells, and appear so far to represent a possible 
replacement for pluripotent ES cells, although much more research will be requried to 
demonstrate whether iPS cells are truly pluripotent and whether they can be used for therapies.  
Adult stem cells are less potent than ES cells, but might have limited uses for treating some 
diseases, although they are difficult to isolate and grow.  The information discussed in this 
chapter will serve as a template for helping interpret our subsequent chapters on stem cell ethics 
and legalities. 
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Chapter-2:  Stem Cell Applications 
Nicholas Kelley 
 
  The application of stem cells to treat chronic diseases, although still in its infancy, shows 
enormous potential for scientific breakthroughs.  This chapter will focus on how stem cells have 
been applied to treating diseases, as the topic of their benefit to society factors strongly into our 
subsequent ethics discussions.  Currently, adult stem cells (ASCs) are already being used to treat 
over 73 different medical conditions, and are the subject of over 1400 specific FDA-approved 
clinical trials (Saunders et al., 2008). These diseases include but are not limited to: autoimmune 
disorders, diabetes, genetic diseases, heart tissue regeneration, breast reconstruction, leukemia, 
organ replacement, neuroblastoma, Parkinson‟s disease, cerebral palsy, sickle cell disease, and 
spinal cord injuries (Saunders et al., 2008).  This chapter will focus on some of these 
applications, including diabetes, heart tissue regeneration, spinal cord injuries, and Parkinson‟s 
disease.  
 To treat any disease with stem cells, one must first establish a stem cell line, regardless of 
what type of stem cell is used.  Establishing a cell line is far easier for embryonic stem (ES) cells 
than with ASCs, as ES cells are far easier to grow.  And in addition, as discussed in Chapter-1, 
ES cells are far more potent than ASCs.  So for these reasons, many researchers perfer to work 
with ES cells for their medical applications in spite of their ethical controversy. 
 
Treating Diabetes with Stem Cells 
 Diabetes currently affects 7% of the world‟s population, and is the sixth leading cause of 
death.  Diabetes is also associated with increased risk for heart disease, stroke, kidney disease, 
blindness, and amputations.  Diabetes accounts for one out of every ten health care dollars 
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currently spent in the US (Goldwaite, 2006).  Although diabetes can currently be managed 
through insulin injections,  it cannot be cured. 
 Diabetes manifests itself in two major forms type 1, and type 2.  In type 1, the body‟s 
immune system identifies the insulin-producing beta cells  (β-cells) of the pancreas as a hostile 
presence, and proceeds to attack them, causing a reduction in the amount of insulin produced and 
a dysregulation of blood glucose.  Type 2 diabetes, afflicting many more than type 1, is 
characterized by insulin-resistance which increases over time.  Figure-1 shows the normal 
checks and balances of glucose homeostasis that are no longer adhered to in diabetic patients.   
 
 
 
 
 
 
 
 
 
 
 
Figure-1:  Diagram of Glucose Homeostasis in the Body.  Shown are the 
main ways in which glucose levels are increased and decreased in the blood, as 
regulated by the hormones insulin and glucagon.  (Keiran, 2009) 
 
 Transplanting β-cells to “cure” type 1 diabetes was first successfully performed in 1990 
at the Washington University Medical Center in St. Louis.  By 2000, many islet transplants had 
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been performed using a so-called Edmonton protocol (named after the University of Alberta in  
Edmonton), which involves isolating islets from cadavers and placing them into the portal vein 
of the diabetic patient.  Unfortunately, this process damages the transplantable tissue, requiring 
β-cells from at least 2-3 cadavers, and along-term study on Edmonton transplant patients showed 
that less than 10% of the recipients remained insulin injection independent after five years.  
Apparently the immune system continued to destroy the implants and the remaining islets.  
 These challenges led researchers to believe that type 1 diabetes may be an appropriate 
candidate disease for stem cell therapy because the damage is initially localized only to a 
particular cell type (Goldwaithe, 2006).  Perhaps ES cells could be grown in culture, then 
differentiated into insulin-producing cells, and placed into the patient.  In fact, it has already been 
shown that, in both mice and humans, ES cells have the ability to differentiate into insulin 
producing cells  (Assady et al., 2001; D‟Amour, 2006).  And these cells have been used to treat 
diabetic mice producing normal glucose regulation.  But this ES cell treatment has not yet been 
performed in humans.  In humans, eventually induced pluripotent stem (iPS) cells could be 
produced from a specific patient, and then differentiated into insulin producing cells that are 
genetically identical to that patient, but this also has not yet been achieved.  Once perfected, this 
technique would eliminate the need for immune suppressing drugs.  
 
Treating Damaged Heart With Stem Cells 
 
 Cardiovascular disease (CVD) is a broad term that includes hypertension, congestive 
heart failure (CHF), stroke, and coronary heart disease.  CVD has been the leading cause of 
death in the U.S. every year since 1900, except for 1918, when there was a large influenza 
epidemic (NIH, 2006).  In 2002, CVD claimed as many lives as cancer, chronic lower respiratory 
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diseases, accidents, influenza, and pneumonia combined (World Health Report, 2004).  Within a 
year of being diagnosed with CHF, one in five people die.  This accounts for the deaths of 
approximately 2600 Americans every day, or one death every thirty-six seconds.  Cardiovascular 
disease also cost about 400 billion dollars in health care costs in FY 2005 (NIH, 2006).  With the 
aging U.S. population and increased incidence of obesity and type 2 diabetes, CVD will become 
an even larger problem in the future.  
 Regardless of which type of CVD strikes, the result is damage to cardiac muscle cells 
(cardiomyocytes) placing a larger burden on the cells that remain. This stress to the heart causes 
the formation of non-contractile scar tissue, ventricle blood thinning, and the stretching of  viable 
cardiac cells. Current methods of treating this problem such as changing the shape of the left  
ventricle, or implanting a pacemaker or defibrillator, while helpful, do not restore function to the 
damaged tissue (NIH, 2006).  Restoring the damaged heart tissue through repair or regeneration, 
represents the best chance of restoring the heart to its normal function. While heart 
transplantation  does offer a viable alternative to replacing damaged tissue or inserting assist 
devices, organ availability and graft vs host disease limit this approach severely. 
 Currently clinical trials using stem cells to repair heart tissue have been performed in 
human patients with adult stem cells (Britten et al., 2003; Siminiak et al., 2004).  But it is too 
early to gauge the effectiveness or make comparisions because of a variety of reasons, including 
differences in the condition being treated, the method of delivery, and the primary outcome 
measured by individual studies.  Despite the issues of comparing the effectiveness of trials to one 
another, the results have been promising.   In 2001, Menashce et al. reported the successful 
implantation of autologous skeletal myoblasts (cells that repair or enlarge voluntary muscles) 
into the scar tissue of a patient with severe ischemic heart failure who was also undergoing 
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coronary bypass.  Examination of the heart five months after surgery showed that the treated 
heart pumped blood more efficiently and seemed to improved the patients' health.  The results of 
this individual study allowed the development of Phase I and Phase II clinical trials. These trials 
included many different stem cell types, including ES cells, skeletal myoblasts (SMs), adult 
bone-marrow derived cells, and adult cardiac stem cells.  Figure-2 shows a basic outline of 
treatment using autologous bone marrow stem cells. 
  
 
 
 
 
 
 
 
 
Figure-2:  Healing a Wounded Heart by Autologous Bone Marrow Stem 
Cells.  (Derbyshire, 2007) 
 
 While skeletal myoblasts are normally committed myogenic producers, their autologous 
origin and high proliferation potential encouraged their use as the first major stem cell type used 
as treatment. Studies in both rats and humans have shown that these cells are able to repopulate 
the scar tissue, improving heart function.  But the major issue with these cells are their inability 
to function in complete harmony with the native heart muscle, creating small heart murmurs.  
Despite this fault, human Phase II studies of therapies using skeletal myoblasts are underway 
(NIH, 2006). 
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 Human adult bone marrow-derived stem cells were proven in 2001 by Jackson et al. to be 
able to regenerate endothelial cells in a mouse heart attack model. Also during 2001, Orlic et al. 
showed that by directly injecting mouse bone marrow-derived cells into damaged heart muscle, 
they could form new cardiomyocytes, vascular endothelium, and smooth muscle cells.  Nine 
days after these stem cells were injected, it was found that “newly formed myocardium occupied 
nearly seventy percent of the damaged portion of the ventricle” (NIH, 2006).  It was also seen 
that survival rates in mice that received the injection were much greater than those that did not.  
However, these results are controversial, as other studies have found no improvement upon 
treatment, so larger trials are currently under way examining this issue more closely. 
 Recent evidence suggests that the heart itself is home to a small population of 
endogenous adult stem cells, helping the heart to facilitate minor repair, as well as replacing 
small numbers of cells do to cell death. These cells have been isolated and characterized in mice, 
rats, and human tissues. These cells however can only be harvested in limited numbers, and 
require separation and expansion ex vivo for several weeks.  Injecting these cells into the scar 
tissue have shown cardiomyocyte formation and improvements in systolic function. Despite the 
limited ability to harvest and grow these cells long term, resident cardiac stem cells are viewed 
by most scientists as a possible replacement for ES cell treatments.  This has led the National 
Heart, Lung, and Blood Institute to fund several clinical trials that will further explore the use of 
these cells as a regenerative medicine. 
 Regardless of which stem cell type eventually becomes the prominent leader in heart 
regenerative therapy, the method in which cells are successfully delivered to the site will play a 
large role. Currently there are three common approaches to insert stem cells into the heart. The 
first is intravenous injection in which stem cells are placed with blood into the patients veins.  
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The second is direct infusion, which is the direct insertion of stem cells into the coronary arteries, 
allowing a more controlled approach of where the stem cells attach. The third approach  is when 
stem cells are injected directly into the ventricular wall, further increasing control of where they 
attach.  However, despite improvements in the delivery efficiency, these methods remain very 
limited due to the high percentage of death of the injected cells.  As many as 90% of the cells die 
shortly after implantation (NIH, 2006). Currently there is another method in development to 
deliver stem cells to the heart. Here at WPI, Genn Gaudette, PhD, an assistant professor in 
biomedical engineering, is attempting to restore function to damaged hearts using bone marrow 
derived stem cells. Professor Gaudette has developed a novel system for “ seeding biopolymer 
micro-threads with hMSCs, then stitching those threads directly into a damaged heart” ( NIH 
Funds, 2009). This technique significantly improves the precision in which stem cells are placed 
into the damaged area, and it may also improve the survival rate of the transplanted cells. 
 
Treatment of Spinal Cord Injuries Using Stem Cells 
 
 Every year 12,000 people in the United States sustain spinal cord injuries. These injuries 
are usually caused by automobile accidents, falls, sports injuries, and gunshot wounds. The 
annual cost of these injuries in 2006 approached ten billion dollars, and may well be over this 
amount currently (Stem Cell Treatment, 2006).  In a spinal cord injury, numerous different cell 
types are damaged. These damaged cells include the neurons that signal from the body to the 
brain and vice versa. While in many injuries the spinal cord itself is not severed, there is a large 
amount of damage to the axons and oligodendrocytes.  The surviving axons cannot carry signals 
strong enough to reach the brain due to the loss of the insulating myelin sheath, which is created 
by oligodendrocytes,  resulting in paralysis.  Even if the myelin sheath is not damaged, it has 
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been shown that while it promotes normal neuronal function, it also inhibits the growth of new 
neurons.   
 Due to the fragile nature and the importance of the spinal cord, researchers first 
established studies on the safety these experiments. The first lab to successfully differentiate 
human embryonic stem cells to become oligodendrocytes was accomplished by Keirstead et al. 
This important study was done on two sets of rats, one that had mild spinal injury, and one that 
had severe spinal injury. In both cases the rats were injected with oligodendrocytes seven days 
after the initial injury. In rats with severe spinal cord injury, the cells were seen to correctly 
migrate to the appropriate site in the spinal cord, and begin forming new myelin sheaths. 
However, those that were only mildly injured showed no increase or decrease in myelin 
production, resulting in no change in their walking ability after transplantation. This study 
proved “ ..in animals that are only slightly injured, the transplantation does not cause visible 
harm, and the injury is not hiding any damage the cells may have caused to the spinal cord or 
surrounding tissue” (Study Establishes 2006).  With this study, researchers can go  into further 
clinical trials without worry that injections would further injure a patient. 
 A treatment developed by Hans Keirstead et al. using human ES stem cells improved the 
mobility in rats with spinal injuries, and provided the first evidence that stem cells were capable 
of helping to treat the damage caused to spinal cords.  This study was done on two groups of rats, 
one that was injected seven days after injury, and another that was injected with the same 
treatment ten months after the injury. The time frames allowed researchers to conclude that most 
spinal cord damage occurs during the first two weeks after injury.  In the rats treated seven days 
after their injury, myelin tissue was found to be forming as oligodendrocytes were beginning to 
wrap themselves around damaged tissue. Two months later the injected rats showed significant 
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improvements in their ability to walk compared to those that received no treatment.  It was found 
that rats treated ten months after their injury did not have their motor skills return to them after 
any length of time.  
 The first human patient treated with hES cells for spinal cord injuries was injected on 
October 11, 2010 by Geron Corporation. “The primary objective of the phase I study was to 
assess the safety and tolerability of human embryonic stem cell-derived oligodendrocyte 
progenitor cells (GRNOPC1) in patients with „complete‟ American Spinal Injury Association 
(ASIA) Impairment Scale grade-A thoracic spinal cord injuries” (US Treats 2010).  Those 
participating in this study must have received their spinal cord injury within fourteen days of 
applying.  Due to the fact that the study is currently in its beginning stages, no further 
information on the effectiveness of this treatment is known. 
 
Treating Parkinson’s Disease with Stem Cells 
 
 Parkinson‟s Disease (PD) is the second most common form of neurological disease. The 
disease manifests itself as a progressive degeneration of midbrain dopamine-secreting neurons. 
Dopamine is the chemical involved in communication between neurons and muscles. It is 
essential for the proper strength and execution of motor function.  As dopamine-secreting 
neurons continue to die, communication is severed, and symptoms appear such as  tremors, 
rigidity of limbs, hypokinesia, and difficulties with walking and balance.  The primary treatment 
for years has been the supplement of dopamine with levadopa.  But this treatment does not stop 
or even slow the progression of the disease at all, and creates Dyskinesia, another movement 
disorder.  The cause of PD is still unknown, but is believed to be a combination of environmental 
and genetic factors, shown below in Figure 3.   
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Figure-3:  The Various Causes of Parkinson’s Disease.  The neuro-
degeneration of PD can be caused by oxidative stress induced by toxins, 
misfolded proteins, mutations in PARK genes, etc.  (Lotharius et al., 2002) 
 
 The first cellular studies attempting to treat PD began in the 1970s, where fetal tissue 
from a mouse substantia nigra was transplanted into an adult rat eye.  These cells were found to 
develop into mature dopamine neurons. Surgeons first attempted to transplant dopamine-
releasing cells into a human brain in the 1980s, and while some patients achieved some relief, it 
was deemed that the risk to the patient out-weighed the benefits.  Due to these trials, the NIH 
funded two large controlled clinical trials beginning in 1988. These trials involved the 
transplantation of tissue from aborted fetuses into patients with PD. Both studies showed 
however only mild benefit, as well as the negative side effect of dyskinesias. Promising findings 
from this trial emerged as well.  It was found that younger patients with only mild PD responded 
well to the grafts.  PET scans of these patients showed that transplanted dopamine neurons had 
survived and were maturing. Researchers in Sweden meanwhile were following transplant 
patients for eleven years after surgery and concluded that the side effect of developing 
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dyskinesias was related to the disruption caused to other cells in the brain during transplant. This 
gives hope that this side effect can be minimized by future improvements in surgical technique. 
 Because PD targets only one specific cell type, like Diabetes, it is a very appropriate 
choice for stem cell therapy. The fragile nature of the brain, and the large incidence of death 
once brain tumors are found, led to studies to establish the safety of stem cell treatments. These 
studies found that when transplanting adult neural stem cells into rats, the cells do not continue 
to divide once differentiated, and none formed tumors. They did not form irregular tissue and 
were found to have normal karyotypes. 
 In 2008, studies in PD patients conducted by the Instituto Brazzini Radiologos Asociados 
in Lima, Peru, using autologous adult stem cells derived from bone marrow injected into the 
patients‟ blood stream, showed “considerable improvement in Parkinson‟s symptoms after stem 
cell implants” (Saunders et al., 2008). Doctors in this study claimed improvement in all forty-
seven patients within one week of treatment. And about 75% of the patients saw a greater than 
50% improvement of symptoms one month after treatment. 
 In 2004, another PD study was done by Michel F. Levesque and colleagues using 
autologous differentiated adult neural stem cells (Levesque et al., 2005).  The patient was 
followed for the next five years to collect data and did not show any adverse side effects to the 
treatment, and at three years post treatment was found according to the Unified Parkinson‟s 
Disease Rating Scale (UPDRS)  to have improved symptoms by 81% while on medication, and 
83% while off medication.  Five years post treatment has shown that the patient‟s motor scores 
had returned to control base-line.  The study concluded that “the combined GABAergic and 
dopaminergic cells produced a long-lasting motor improvement. This approach has the potential 
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to make neural stem cell therapy acceptable and available to a large number of patients” 
(Levesque, 2009).  These results give hope that a cure for PD lies in the foreseeable future. 
 While there have been many advancements in stem cell therapies in the recent past, there 
still remains great potential for future treatments of other chronic or terminal diseases. Stem cell 
treatments may one day lead to regenerating lost limbs or injured organs, and could have a major 
impact on patient‟s quality of life. 
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CHAPTER-3:  STEM CELL ETHICS 
Kathleen Foust 
 
In the previous two chapters we discussed the technology of stem cells, describing their 
various types and how they can be used to benefit society.  But so far we have not discussed 
whether we should be working with these cells.  In this chapter we focus on the ethics of stem 
cells, including various religious perspectives and the author‟s point of view. 
 
The Main Stem Cell Ethical Questions 
The debate on stem cells invariably focuses on one type of stem cell, embryonic stem 
(ES) cells, and when life begins.  As discussed in Chapter-1, ES cells are isolated from 5-day old 
blastocysts created by in vitro fertilization (IVF).  When ES cells are isolated from the blastula‟s 
inner cell mass, it destroys the embryo, so the ethics of ES cells focuses on whether the 
destruction of IVF blastulas constitutes “murder”.   
In addition to discussing whether embryos should be destroyed to obtain ES cells, 
ethicists also focus on the topic of the source of the embryos.  If ES cells are to be used, should 
the embryos only be obtained from IVF clinics, where they were originally created for 
reproductive purposes but are now slated for discard?  Or is it allowable to create embryos solely 
for research purposes?   Each US President and Congress has grappled with these important 
questions when designing laws for stem cell use (discussed in Chapter-4). 
Science vs. religion has been one of the hottest debated topics for the past several 
hundred years.  When it comes to when life begins, each religion has its own perspective, so it‟s 
hard to discuss which is the “correct”, and each individual has his own beliefs.  Does life begin at 
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conception, as Catholics believe?  Or does it begin when the baby actually is born, or somewhere 
in between?  Ethics is a balancing act between the benefits to society versus the detriment to the 
embryo.  Is it murder to kill an embryo, or does the benefit of saving existing lives over come 
this negative?   
With respect to adult stem cells (ASCs), contrary to the situation with ES cells, none of 
the five major religions are against using them for research and treatments.  Isolating and 
growing ASCs does not require any embryos, so even the conservative Catholic Church is in 
favor of ASC research so long as lives are being saved, as stated by Pope Benedict XVI 
(Catholic Online, 2008). 
 
Islam and Stem Cells 
There is no explicit Islamic ruling on the topic of stem cells (Pew Forum, 2008).  
But in general, Muslims believe that life begins about day-40 of development, which is well past 
the day-5 blastocyst, and they make a distinction between the early stages of development (up 
through day-40 where the embryo has less value) and the later stages of development where it 
has more value (Siddiqi, 2002).  And since IVF embryos are not in a womb, they will not 
develop into a human being, so they put less emphasis on IVF embryos.  Thus, many in the 
Islamic community support ES cell research.  When the followers of this religion were asked, a 
majority were in favor of using embryos for stem cell research.  Islam‟s followers are in support 
of ES cell research because they believe that the extra embryos from IVF should not be just 
discarded but rather used for research (Ahmed, 2001).  When polled, 62% agreed with the 
overall support for research on human embryos, and 43% said it was acceptable to produce 
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embryos for research proposes only (Ahmed, 2001).  These percentages show that a majority of 
Muslims are in favor of using ES cell research.  
 
Christianity and Stem Cells 
Although Christianity is in favor of using ASCs, this large religion has many subsets that 
disagree on the use of ES cells and embryos.  One subset of the Christian religion, Catholicism 
has strong opinions against ES cells, as they believe that life begins at conception, which rules 
out working with embryos.  When former President Bush was at one time considering allowing 
limited funding for ES cell research, the US Bishop Fiorenza, President of the US Catholic 
Conference of Bishops, was quick to oppose (American Catholic…2006).  Fiorenza even stated 
“… it allows our nation's research enterprise to cultivate a disrespect for human life” (American 
Catholic….2006).  Bush eventually issued his 2001 mandate declaring that no federal money 
will be spent deriving new embryos or ES cell lines (discussed in Chapter-4).   On the other 
hand, Pope Benedict XVI endorsed his support for ASC research (Catholic Online, 2008). It is 
imperative for the religion to support some type of stem cells so that they can be used to benefit 
humanity. 
Within Christianity, however, other subsets support ES cell research, including the 
Methodists and Episcopalians (United Methodist Church, 2004; Faithful Progressive, 2005). 
 
Judaism and Stem Cells 
 Along with Christianity and Islam, Judaism is in favor of using ASCs (Jakobovits 2002). 
However, when it comes to ES cell usage they have various circumstances in which they can and 
cannot be used.  In general, those of the Jewish faith believe that human status is obtained after 
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40 days of gestation, and that the fetus only achieves full personhood at birth (Dorff, 2001). So 
prior to 40 days the IVF embryo is not a human, and Jewish law allows research on 5 day old 
embryos.  Jewish law does not allow post implantation tissue, an embryo that has already been 
implanted in the uterus to be used for research, but if the fetus causes harm to the mother in any 
way then it is allowed to be removed and possibly used for research (Jakobovits, 2002).  Thus, 
Judaism is in favor of using both ASCs and ES cells, under the appropriate conditions, especially 
if the stem cells are being used for medical purposes (Pew Forum, 2008).  
 
Buddhism and Stem Cells 
The Dalai Lama has put a significant amount of thought about the scientific process, to be 
able make educated decisions research advances.  The Dalai Lama even meets with leading 
scientists on a yearly basis to explore ethical questions (Dalai Lama, 2003).  It is important for 
religious leaders, philosophers, and scientists to meet to discuss current topics such as stem cells, 
so that each group can have well educated decisions on the matters at hand.  Buddhism is divided 
on the topic of stem cells, as the Dalai Lama states, “From the classical Buddhist standpoint [of 
doing no harm], it has become a sentient being and extermination of that would be morally 
equivalent, almost, to killing a human being (Dali Lama, 2003). On the other hand, Buddhism 
supports research that has “compassionate motivation”, meaning that if the intentions of the 
scientists are pure then it is permissible to carry out the research (Dali Lama, 2003).  Because the 
scientists researching stem cells are doing so to produce treatments for diseases, it can be implied 
that they are practicing good intentions.  The two tenets that divide the Buddhist community are 
1) the prohibition of harming or destroying others, and 2) the pursuit of knowledge and 
compassion (Pew Forum, 2008).  With respect to Buddhism and when life actually begins, 
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according to the Dalai Lama it is more of a grey area.  He believes that there has to be more to 
life than just a fertilized egg, it has to have some sort of consciousness to become a human life 
(Dali Lama, 2003).  
 
Hinduism and Stem Cells 
Hinduism supports ASCs research, however when it comes to ES cells, Hindu‟s believe 
that life begins at conception, meaning it would kill a life to destroy a 5 day old embryo 
(Manickavel, 2004).  However, Hindu‟s also recognize the difference between people and 
embryos, as they support abortion if the mother‟s life is at stake (Manickavel, 2004). These 
views appear to be contradicting, as it is acceptable to “murder” an embryo to save the life of the 
mother, so then scientists should be able to use ES cells to save people from terrible diseases. 
Hindus give higher significance to an already existing human that has existed longer than the 
embryo.   
One interesting aspect of the Hindu debate about stem cells is they are strongly against 
any process where only the rich will benefit (Dharma Discussions, 2003; Manickavel, 2004). 
Hinduism traditionally looks out for the poor.  In medicine, most early stages of drug 
development are extremely expensive, so when the drugs are first placed on the market they are 
expensive which benefits the rich and the pharmaceutical companies produce the drug. Therefore 
it will take a significant amount of time for the poor to be able to access the drugs, making it a 
moral controversy for the Hindus regarding the creation and distribution of the treatments.  
Overall, Hinduism does not support killing an embryo, but they do support saving lives with 
ASCs. 
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The Author’s Personal Opinions  
 Personally, I believe that a 5-day embryo does not have the same moral status as a living 
person; they have the potential to become a person but are not yet a full person.  At five days 
post-fertilization, the embryo has not even had the chance to attach itself to the endometrium 
lining of the uterus.  At around 2 months, after the embryo has attached to the uterus and 
developed to begin looking like a human, I give it higher moral status.  With respect to IVF 
embryos, I believe the excess embryos originally created for reproductive purposes by couples, 
who have had enough children, and who give their consent to use the embryos for research, 
should be used to create more ES cell lines to benefit someone who is already alive. 
I am also in favor of producing embryos solely for research purposes. If these stem cells can help 
save lives then they should be created to do so. People should be able to decide whether to allow 
their embryos to be used for ES cell research. These people should be fully educated on all sides 
of the stem cell debate to make an educated personal decision. And when making this choice, 
they should not have to be swayed one way or another, for scientific or religious points of view.   
 With respect to using adult stem cells, I am in favor of using them as long as they are 
used to maximally benefit the patient. If the ASCs perform better in some cases than ES cells, 
then they should be used.  Whether ASCs should be used in treatments because they are 
“ethically” better to some should not be a factor.  Patients should be able to receive the best 
treatment for their disease, even if this involves ES cells. When treating a specific disease, if ES 
cells and ASCs are shown to have exactly the same ability to treat that particular disease, I agree 
that ASCs should be used first, as a nod to others who view ES cells as controversial. 
 With respect to induced pluripotent (iPS) cells, I am in favor of using them if they are 
shown to help a particular disease.  These cells do not involve destroying an embryo, and they 
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are less ethically controversial than ES cells.  Again as a nod to others who find ES cells 
ethically controversial, I would use iPS cells before ES cells in treatments if they work.  But if 
ES cells are shown to work much better for a particular disease, I am not against using ES cells 
to treat that particular disease. 
 Overall, I am in favor of using all types of stem cells. The benefits to the treated 
individual, and society, outweigh the ethical controversies, and so scientists should be allowed to 
use whichever stem cell works best for that particular disease. 
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Chapter-4:  Stem Cell Legalities 
Nicholas Kelley 
 
 
 Research using human embryonic stem (hES) cells is one of the most controversial topics 
not only in the U.S. but around the world.  Because many ethical and moral issues must be 
considered when working with hES cells, laws have been enacted to regulate their use and 
funding; this chapter will investigate these laws. 
 
Federal Stem Cell Laws in the U.S. 
 
 Because the U.S. is a Democratic Republic, it has executive orders issued by the 
President, and laws enacted by Congress.  And there has been much fluxuation in these laws over 
the years, depending on which President was in office, and which party had control of Congress 
at the time.  This led over the years to an inconsistent funding of hES cell research. This 
inconsistency and fear that their funding will be removed has left many scientists wary of this 
field, hindering the development of therapies. This section will be a consolidation of previous 
laws passed at the federal level. 
 The first of these federal laws was passed by Congress on July 12th, 1974, which banned 
all federally funded Fetal Tissue Research, while establishing the National Commission for the 
Protection of Human Subjects of Biomedical and Behavioral Research.  This commission was to 
devise guidelines for the protection of human subjects during medical or other scientific 
experiments.  One year later in 1975, the commission established its guidelines, creating an 
ethics advisory board for fetal and fetal tissue research originating from abortions. (Stem Cell 
Tracker, 2009) 
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 In 1980, President Reagan decided not to renew the Ethics Advisory Board's charter, 
which effectively denied their recommendation that  federal funds be used for investigation of 
the safety of in vitro fertilization. The disbandment of the board resulted in a lack of federal 
funding for human embryo research. In 1988, a Federal panel voted to reopen this issue, and 
voted 18-3 in favor of approving federal funding of embryo research. However, the Department 
of Health and Human services accepted the testimony of the three dissenters, and extended this 
moratorium on funding this research. Congress attempted to override this moratorium again in 
1990, but President George H.W. Bush vetoed the bill. 
 In 1993, President Clinton issued an executive order stating that the moratorium be lifted, 
and the Department of Health and Human Services Secretary, Donna Shalala, lifted the 
moratorium on federal funding of research according to President Clinton‟s order. In 1994 
however, the President reversed his order due to the large amounts of letters received, so federal 
funding again was withheld from human embryonic research. In 1995, Congress banned the 
federal funding of research on embryos through the Dickey-Wicker Amendment. This removed 
federal funding for "the creation of human embryo or embryos for research purposes; or research 
in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of 
injury or death greater than that allowed for research on fetuses in-utero" (Stem Cell Tracker, 
2009).  This amendment however did not state that federal funds could not be allocated to 
researchers using embryos donated from in vitro fertilization clinics (with donor permission) 
after the donors no longer required them.  This amendment, as with all previous orders and laws, 
did not prohibit research that is privately funded. 
 In 1998, James Thomson was the first to isolate hES cells at the University of Wisconsin. 
This discovery lead to a large ethical debate due to the process in which these cells are isolated, 
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which also  involves  the destruction of the IVF embryo.  In January of 1999, the department of 
Health and Human Services General Council, Harriet Rabb, gave a legal opinion to the National 
Institute of Heath Director Harold Varmus that the Dickey-Wicker Amendment does not apply to 
funding on research of ES cells. This opinion arose due the inability of these ES cells to meet the 
definition of an embryo. These new human ES cells however required an embryo to isolate them, 
therefore this research would still initially have to be derived with private funding. Later that 
year, Director Varmus appointed an oversight committee to deal with draft guidelines for 
federally funding ES cell research. Due to the large ethical issues inherent in these cells, this 
committee included many different professionals, including lawyers, ethicists, scientists, patent 
sponsors, and patients. The NIH then developed guidelines for funding of  hES cell research over 
the next few months.  But the NIH did not actually fund any research proposals then due to 
presidential candidate George W. Bush's opposition to the research. 
 In August of 2000, the NIH published guidelines for research using human pluripotent 
stem cells.  The guidelines specifed that human embryonic stem cells must be derived with 
private funds from frozen embryos from fertility clinics; they must have been created for fertility 
treatment purposes; be in excess of the donor's clinical need; and obtained with the consent of 
the donor (Stem Cell Tracker, 2009).  One year later, newly inaugurated President Bush 
prohibited federal funding of any research using ES cell lines derived after August 9, 2001.  But 
this did not affect private sector or state funded research, claiming that this still leaves sixty stem 
cell lines viable for federal funding.  However it was later determined that only twenty-one of 
these lines were feasible for research, limiting research drastically. 
 In 2007, President Bush issued an executive order supporting and encouraging research 
on alternative sources of pluripotent stem cells. Later that year Yamanaka and Thomson both 
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independently published papers discovering how to create induced pluripotent stem (iPS) cells. 
This discovery gave hope that the ethical dilemmas of ES cell research may one day be 
inconsequential.  In 2009, President Obama upholding his campaign promises, issued the 
following executive order: 
 
 THE WHITE HOUSE  
Office of the Press Secretary 
_________________________________________ 
For Immediate Release       March 9, 2009 
EXECUTIVE ORDER 
- - - - - - - 
REMOVING BARRIERS TO RESPONSIBLE SCIENTIFIC 
RESEARCH INVOLVING HUMAN STEM CELLS 
By the authority vested in me as President by the Constitution and the laws of the United States of America, 
it is hereby ordered as follows:  
Section 1.  Policy.  Research involving human embryonic stem cells and human non-embryonic stem cells 
has the potential to lead to better understanding and treatment of many disabling diseases and conditions.  
Advances over the past decade in this promising scientific field have been encouraging, leading to broad 
agreement in the scientific community that the research should be supported by Federal funds. 
For the past 8 years, the authority of the Department of Health and Human Services, including the 
National Institutes of Health (NIH), to fund and conduct human embryonic stem cell research has been 
limited by Presidential actions.  The purpose of this order is to remove these limitations on scientific 
inquiry, to expand NIH support for the exploration of human stem cell research, and in so doing to enhance 
the contribution of America's scientists to important new discoveries and new therapies for the benefit of 
humankind. 
Sec. 2.  Research.  The Secretary of Health and Human Services (Secretary), through the Director of NIH, 
may support and conduct responsible, scientifically worthy human stem cell research, including human 
embryonic stem cell research, to the extent permitted by law. 
Sec. 3.  Guidance.  Within 120 days from the date of this order, the Secretary, through the Director of NIH, 
shall review existing NIH guidance and other widely recognized guidelines on human stem cell research, 
including provisions establishing appropriate safeguards, and issue new NIH guidance on such research 
that is consistent with this order.  The Secretary, through NIH, shall review and update such guidance 
periodically, as appropriate. 
Sec. 4.  General Provisions.  (a)  This order shall be implemented consistent with applicable law and 
subject to the availability of appropriations. 
(b)  Nothing in this order shall be construed to impair or otherwise affect: 
(i)   authority granted by law to an executive department, agency, or the head thereof; or  
(ii)  functions of the Director of the Office of Management and Budget relating to budgetary, 
administrative, or legislative proposals. 
(c)  This order is not intended to, and does not, create any right or benefit, substantive or procedural, 
enforceable at law or in equity, by any party against the United States, its departments, agencies, or 
entities, its officers, employees, or agents, or any other person.  
Sec. 5.  Revocations.  (a)  The Presidential statement of August 9, 2001, limiting Federal funding for 
research involving human embryonic stem cells, shall have no further effect as a statement of governmental 
policy. 
(b)  Executive Order 13435 of June 20, 2007, which supplements the August 9, 2001, statement on human 
embryonic stem cell research, is revoked.  
 
 (Whitehouse.gov) 
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The Obama order had an immediate worldwide effect, with many scientists celebrating the 
removal of one of the fields major roadblocks. This executive order raised the number of stem 
cell lines available for federal funding from a meager twenty-one to a much larger pool, with 
estimates ranging from 400 to 1000 lines. The large allowance in the various estimates is due to 
the rigorous screening process an ES cell line must pass before being permitted for federal 
funding. 
 
 
U.S.  State  Stem Cell Laws and Funding  
 
 Many state laws that affect stem cell research have been enacted to allow state funding of 
ES cell research, and to address other pressing ethical issues such as abortion and in vitro 
fertilization. There are four sources of ES cells: aborted or miscarried embryos, unused in vitro 
fertilized (IVF) embryos, cloned embryos, and established stem cell lines. While there is no 
federal law banning human therapeutic cloning in the U.S., the FDA has taken it upon itself to 
declare that human cloning would be a new investigational drug, and would not approve any 
projects of this kind. This eliminates the possibility of individual states passing laws funding this 
type of research (Stem Cell Research, 2008).  As seen in Figure-1 below, individual states have 
the ability to regulate stem cell research completely, taking various stances from banning the 
research altogether, to funding ES cells. This creates an interesting and sometimes hostile 
environment.  
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Figure-1:  Individual States and Stem Cell Laws.  States shown in dark pink 
support ES cell research with funding.  States shown in light pink allow the 
research, but provide no funding.  States shown in yellow ban the research.  
States shown in gray have no laws on the ES cell research (Vestal, 2009) 
 
 The first state to support ES cell research was New Jersey, which in 2004 allocated one 
million dollars every year for ten years to research. Since then, they have allocated an additional 
15 million dollars for grants, and 9.5 million dollars for administration costs.  California later 
that year passed Proposition 71, which allowed for three billion dollars towards funding stem cell 
research. However, due to legal issues over who would later have the rights to patents resulting 
from future discoveries, this funding was withheld for a time. Governor Schwarzenegger 
distributed 150 million dollars to this program two years later due to the still ongoing legal patent 
battle. 
 Following their supporting examples, Connecticut passed Senate Bill 934 in 2005, 
creating a fund to provide ten million dollars a year, every year for the next ten years for the 
advancement of stem cell research. This bill also proposed guidelines, advisory panels, and a 
peer review board to oversee the funds, ensuring the regulation of new research. 
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 Massachusetts has also been in the spotlight produced by stem cell research. After an 
initial bill was passed by the legislature which was intended to place Massachusetts at the front 
of ES cell research, then Governor Mitt Romney vetoed the bill.  However, the bill then passed 
back to the house and senate for a new vote.  Both the House of Representatives (112-42) and the 
State Senate (35-2) not only voted in favor of the bill once more, but achieved more than two-
thirds votes in each body, over riding the governor's veto. Not to be outdone by the previous 
legislation, Governor Patrick pushed for new legislation committing one billion dollars to stem 
cell research. On June 6th 2008, Governor Patrick signed the Life Sciences Initiative into law, 
stating that: 
"Tomorrow, when the Life Sciences community gathers from around the world at 
the BIO Conference in California, Massachusetts will have a new and broader set 
of tools to help us compete. Massachusetts will have the largest registry of stem 
cell lines in the world, housed at the University of Massachusetts Medical Center 
in Worcester. Massachusetts, will have a half-billion dollars in capital funding to 
offer entrepreneurs, for infrastructure investment and economic growth. 
Massachusetts will have 250 million dollars to offer researchers for fellowships, 
matching grants and loans to attract and retain rising stars in this field. 
Massachusetts will have incentives to offer companies to locate and expand here 
and five regional tech/innovation centers to extend these opportunities to every 
region of the Commonwealth."  ( Life Science Bill Signing, 2008) 
 
International Stem Cell Legislation 
 
 The United States is not the only major player in stem cell research. In the last ten years 
or so, several European and Asian countries have become leaders in varying aspects of the field. 
They, along with at least one major country from each continent, have drastically expanded the 
depth of knowledge pertaining to stem cells, techniques, and applications.  Figure-2 shows a 
world map of the various countries that allow (dark brown), limit (lighter brown), disallow or 
have no stance on (yellow) ES cell research (Vestal, 2009).  On December 21st, 2006,  The 
 43 
International Society for Stem Cell Research released its first "Guidelines for Conducting 
Human Embryonic Stem Cell Research."  
 
 
  
Figure-2:  International Stem Cell Laws. Shown is a world map of the 
various countries that allow (dark brown), limit (lighter brown), disallow 
or have no stance on (yellow) ES cell research.  (Vestal, 2009) 
 
The Middle East, while normally viewed as conservative due to traditional dress and customs, 
does in fact allow and endorse stem cell research. In 1999, Israel passed legislation which 
banned reproductive cloning, but this country does not ban therapeutic cloning, allowing 
researchers to continue to have access to ES cells.  Israel was in fact the first to extract stem cells 
from blood, and is currently focused on regenerative medicine. Saudi Arabia first became active 
in stem cell research in 2002. A legal decree, issued by religious officials, sanctioned the use of 
embryos for production of stem cells and therapeutic research. 
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 In South America, Brazil passed laws in 2005, permitting ES cell research, with 
regulations stating that the embryos must have been frozen at least three years before becoming 
eligible for research. Soon after these laws were passed, a petition endorsed by the Catholic 
Church of Brazil, challenged the law, stating it was in violation of the "right to life." This 
petition remained in the courts for three years until being rejected by Brazil's Supreme Court. 
 In North America, Mexico has a powerful stem cell industry due to its lack of any formal 
regulations on stem cell research. Doctors are already treating chronically ill patients with stem 
cells. However due to their lack of any regulations, Mexico has lost some respect in the eyes of 
the international medical community. In 2006, Canada also began endorsing stem cell research. 
Canada prohibits the creation of human embryos for research, allowing only extra embryos 
designated for destruction from in vitro fertilization be used. This eliminates much of the ethical 
debate over the issue, as the embryos will die in either scenario. 
 Asia has also contributed largely to our knowledge of stem cell research. China, while 
prohibiting reproductive cloning, allows the creation of human embryos for research and 
therapeutic purposes. India is known for its large stem cell banking initiative. It however has 
banned reproductive cloning, and currently limits the use of stem cells to bone marrow 
transplants.  In 2007, Japanese and American researchers discovered the ability to turn adult 
human stem cells into induced pluripotent cells. South Korea lost a large deal of trust in 
international credibility due to fraudulent claims by Dr. Hwang Woo-suk who claimed to have 
achieved human therapeutic cloning. But despite this setback, South Korea still promotes 
therapeutic cloning of embryos for stem cell research. 
 Europe has also contributed largely to the attention stem cells are receiving. The United 
Kingdom's Ian Wilbut and team were the first to successfully clone an animal in 1996, which 
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resulted in Dolly the world famous sheep. Scientists in the U.K. in 2005 were also the first to 
successfully clone a blastocyst. Sweden is also a biomedical powerhouse backed by its public 
and politicians, and it limits its research to therapeutic cloning. Germany wary of new medical 
research due to experiments conducted during World War II, finally authorized the use of 
imported ES cell lines in 2008. 
 Due to the large ethical issues brought about by ES cell research, a wide array of laws 
regarding life have been enacted. The wide range of laws is especially seen in the U.S. with 
individual states either strongly supporting the research, or banning it altogether. 
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PROJECT CONCLUSIONS 
 
 
 This project investigated the topic of stem cells and the impact of this technology on 
society through ethics and laws.  We documented the various types of stem cells, paying special 
attention to each of their ethical status.  Working with any type of adult stem cell (ASC) does not 
destroy an embryo, so these cells have few ethical concerns.  However ASCs are hard to isolate, 
do not grow well in culture, and do not have the strong medical potency of embryonic stem (ES) 
cells.  ES cells are relatively easy to isolate and grow in culture.  Thus, in spite of the ethical 
controversy of ES cells, such cells may be the best for medical therapies.  The authors of this 
IQP believe that research on ES cells should be allowed, with strong oversight.  In particular, due 
to their ethical controversy, we agree that the source of embryos for ES cell research should be 
from IVF embryos originally created for reproductive purposes.  As a further acceptance of the 
ES cell controversy, the authors also agree that ASCs should be used for therapies if the ASC 
research shows that those cells are as effective as ES cells, if not, ES cells should be used.  With 
respect to stem cell laws, the authors believe that countries such as Sweden or China, which 
allow ES research and paid embryos donations, are laws we most agree with, which should be 
implemented in the US. 
